CEO / Co-Founder
MPC Therapeutics
MPC Therapeutics develops MitoStemX, a universal media supplement designed to enhance the fitness and persistence of T cell therapies. This chemically defined, animal component-free supplement targets T cell metabolism using two small molecules to improve therapeutic efficacy and durability. The product is compatible with various CAR/TCR constructs and clinical-grade cell culture media, enabling reliable production of efficient cell therapy products.
- Biotechnology
Updated 16 months ago
Funding
Raised to date
$112.5KRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- MPC Therapeutics develops a novel class of compounds targeting immune modulation and metabolic regulation to enhance therapeutic outcomes in immunotherapy and metabolic diseases. Their approach aims to improve patient responses and reduce side effects associated with current treatment options.